8-K: Edwards Lifesciences Reports Strong Q1 2025 Results, Raises TMTT Sales Guidance

Edwards Lifesciences announced positive first-quarter 2025 financial results, driven by growth in TAVR and TMTT, and raised its TMTT sales guidance for the year.

Summary

• Edwards Lifesciences reported a 6.2% increase in first-quarter sales, reaching $1.41 billion.
• Adjusted sales growth was 7.9%.
• TAVR sales grew by 3.8%, or 5.4% on a constant currency basis.
• TMTT sales saw substantial growth of 58%, reaching $115 million.
• The company's Q1 EPS was $0.62, with an adjusted EPS of $0.64.
• Edwards is raising its 2025 TMTT sales guidance to a range of $530 million to $550 million.
• The company is reiterating its TAVR and Surgical sales growth guidance.
• Total company sales guidance is increased to $5.7 to $6.1 billion.
• Adjusted EPS is reaffirmed at $2.40 to $2.50, which includes the estimated JenaValve dilution and tariff impact.
• For the second quarter of 2025, the company projects total sales to be between $1.45 and $1.53 billion and adjusted EPS of $0.59 to $0.65.

Sentiment

Score: 8

Explanation: The report is positive due to strong sales growth, raised guidance, and key product approvals. However, there are some concerns about margin pressure from currency and tariffs.

Positives

• Strong sales growth in Q1, driven by TAVR and TMTT segments.
• TMTT portfolio is showing impressive growth and contributing meaningfully to overall performance.
• The company's competitive position and pricing remained stable globally.
• Edwards is advancing initiatives to help hospitals treat structural heart patients efficiently.
• The company is encouraged by discussions with key clinicians on the long-term impact of the EARLY TAVR data to streamline patient care.
• The recent CE Mark approval of the SAPIEN M3 in Europe will benefit many patients with mitral regurgitation who have limited treatment options.
• MITRIS launched in China with positive surgeon feedback.

Negatives

• The company expects pressure on its operating margin as a result of the weakening dollar, the impact of announced tariffs and the expected close of the JenaValve acquisition.

Risks

• Fluctuations in currency exchange rates could impact future results.
• Tariffs could have a material impact on the company's future financial results and guidance.
• The company's forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements.

Future Outlook

Edwards is raising its 2025 TMTT sales guidance range to $530 to $550 million and increasing total company sales guidance to $5.7 to $6.1 billion. The company reaffirms its adjusted EPS guidance of $2.40 to $2.50.

Management Comments

• Collectively, these milestones mark the significant progress we have made to unlock this large and growing opportunity to transform care for millions of structural heart patients around the world, said Bernard Zovighian, CEO.
• We are pleased with our strong start to the year and have confidence in our 2025 outlook.
• Looking to the future, we will build on the many impactful catalysts for our company, which position us for distinguished growth in the years ahead.

Industry Context

Edwards Lifesciences is a leading player in the structural heart market, competing with companies like Medtronic, Abbott, and Boston Scientific. The growth in TAVR and TMTT reflects the increasing adoption of minimally invasive procedures for treating heart valve diseases. The CE Mark approval for SAPIEN M3 positions Edwards favorably in the mitral valve replacement market.

Comparison to Industry Standards

• Edwards' TAVR growth of 3.8% is in line with the overall market growth, but the TMTT growth of 58% significantly outpaces competitors in that emerging space.
• Medtronic and Abbott are also investing heavily in TMTT, but Edwards' EVOQUE and PASCAL platforms appear to be gaining traction.
• The SAPIEN M3 approval gives Edwards a first-mover advantage in the transcatheter mitral valve replacement market, similar to how SAPIEN initially led in TAVR.

Stakeholder Impact

• Shareholders will likely react positively to the strong results and raised guidance.
• Clinicians and patients will benefit from the continued innovation and expansion of treatment options.
• Employees are likely to be motivated by the company's strong performance and future prospects.

Next Steps

• The company anticipates asymptomatic indication approval in the second quarter.
• Edwards expects to receive CE Mark approval for the KONECT aortic valved conduit in Europe before year-end.
• The company will host a conference call to discuss the first quarter results.

Key Dates

Keywords

Edwards Lifesciences, TAVR, TMTT, Surgical, Financial Results, Sales Growth, EPS, Guidance, Structural Heart, RESILIA, SAPIEN, EVOQUE, PASCAL, MITRIS, KONECT, JenaValve